Physician profile
Johnne Leoncio
NPI 1578060786
$1,214.20
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $961 · 2022: $231 · 2024: $22.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $163.21 | 2021 | |
| Novo Nordisk INC | $136.32 | 2021 | |
| Cmp Pharma, INC. | $101.58 | 2021 | |
| Lilly USA, LLC | $94.37 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $75.46 | 2021-2022 | |
| Kyowa Kirin, INC. | $71.48 | 2021 | |
| Vanda Pharmaceuticals INC. | $61.76 | 2021 | |
| Eisai INC. | $52.39 | 2021 | |
| Astellas Pharma US INC | $47.82 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.53 | 2022 | |
| Abbvie INC. | $45.42 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $44.84 | 2022 | |
| Sun Pharmaceutical Industries INC. | $43.54 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.07 | 2022 | |
| Merck Sharp & Dohme LLC | $33.38 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $24.48 | 2021 | |
| Phathom Pharmaceuticals, INC. | $22.49 | 2024 | Voquezna |
| Avanir Pharmaceuticals, INC. | $18.91 | 2021 | |
| Nabriva Therapeutics, Plc | $18.89 | 2021 | |
| Adamas Pharmaceuticals, INC. | $18.41 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.30 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.77 | 2021 | |
| Almatica Pharma LLC | $14.58 | 2021 | |
| Genentech USA, INC. | $7.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnne Leoncio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.